© 2001 American Heart Association, Inc.
Editorials |
Retinoids: New Insight Into Smooth Muscle Cell Growth Inhibition
From the Center for Cardiovascular Research, University of Rochester Medical Center, Rochester, NY.
Correspondence to Joseph M. Miano, PhD, Center for Cardiovascular Research, Box 679, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642. E-mail Joseph_Miano@urmc.rochester.edu
Key Words: retinoid • restenosis • smooth muscle proliferation and differentiation • growth factors/cytokines
The successful management of vascular occlusive diseases, particularly those due to procedural interventions for preexisting atherosclerosis, will likely require the targeting of numerous cellular processes rather than any 1 gene, protein, or signaling pathway. This fact is underscored by the failure of virtually all clinical trials employing pathway- or factor-specific therapeutics to limit restenosis after percutaneous vascular interventions. Retinoids are natural and synthetic derivatives of vitamin A that exert myriad effects on such cellular processes as growth, apoptosis, differentiation, and migration. As such, retinoids could be potential therapeutics to test in the context of vascular occlusive disease.1 2 3 4 Clinically, the prototypic natural retinoid, all-trans retinoic acid (atRA), effects a nearly 100% rate of remission in patients with acute promyelocytic leukemia.5 Given the similarities in the pathogenesis of neoplasia and vascular occlusive lesions (ie, increased cell growth and loss of cellular differentiated properties), it is surprising that retinoids have only recently been examined with respect to cells of the vascular wall.
Many retinoids exert their pleiotropic effects through
the binding and activation of nuclear retinoid receptors. There are 2
families of retinoid receptors, each of which comprises 3 distinct
genes. The retinoic acid receptors (RAR 
, ß, and 
) bind atRA
and its 9-cis stereoisomer
(9cRA), whereas the more weakly expressed retinoid X receptors (RXR
, ß, and ) bind
9cRA.6 Numerous retinoids
have been synthesized and tested for receptor selectivity as a means of
reducing the side effects associated with natural retinoid therapy.
Many of these synthetic retinoids have
This article has been cited by other articles:
 |
|
 |
|
  B. Zheng, M. Han, M. Bernier, X.-h. Zhang, F. Meng, S.-b. Miao, M. He, X.-m. Zhao, and J.-k. Wen Kruppel-like Factor 4 Inhibits Proliferation by Platelet-derived Growth Factor Receptor {beta}-mediated, Not by Retinoic Acid Receptor {alpha}-mediated, Phosphatidylinositol 3-Kinase and ERK Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., August 21, 2009; 284(34): 22773 - 22785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Kolodziejska, M.H. Noyan-Ashraf, A. Nagy, A. Bacon, J. Frampton, H.-B. Xin, M. I. Kotlikoff, and M. Husain c-Myb-Dependent Smooth Muscle Cell Differentiation Circ. Res., March 14, 2008; 102(5): 554 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saito, A. Sugawara, A. Uruno, M. Kudo, H. Kagechika, Y. Sato, Y. Owada, H. Kondo, M. Sato, M. Kurabayashi, et al. All-trans Retinoic Acid Induces in Vitro Angiogenesis via Retinoic Acid Receptor: Possible Involvement of Paracrine Effects of Endogenous Vascular Endothelial Growth Factor Signaling Endocrinology, March 1, 2007; 148(3): 1412 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Baxter, W. F. Young Jr., and P. Webb Cardiovascular Endocrinology: Introduction Endocr. Rev., June 1, 2003; 24(3): 253 - 260. [Full Text] [PDF]
|
|